• AI Algorithm Advances Cancer Diagnostics Through Rapid Cell Type Identification

    Aug 05 | Diagnostics World | Researchers at Virginia Commonwealth University have developed an artificial intelligence tool that could revolutionize cancer diagnostics by rapidly identifying distinct cell types in tissue biopsies, potentially transforming how clinicians make treatment decisions and predict patient responses to therapy. More

  • UK Biobank Whole Body Imaging Project, Longhorn Vaccines and Diagnostics, Promega Partner Up, More

    Jul 31 | Diagnostics World | UK Biobank completed the world’s largest whole body imaging project; Longhorn Vaccines and Diagnostics announced a strategic co-marketing agreement with Promega Corporation; and more. More

  • Follow the Money: Rheumatoid Arthritis Prediction Test, GAIA-based Alzheimer’s Therapeutics, More

    Jul 30 | Diagnostics World | Aqutal’s advance toward a therapy response prediction test in rheumatoid arthritis; Illimis Therapeutics plans to accelerate the development of GAIA-based Alzheimer's disease therapeutics and various immune disorders; and more. More

  • Glowing Molecule Helps Surgeons Quickly Visualize Tumor Margins

    Jul 24 | Diagnostics World | A surge in research and development around fluorophores, various types of glowing molecules used to enhance visualization during surgical procedures, is driving excitement about their potential to improve the performance of human surgeons and “pave the way” for even better autonomous robotic surgery. More

  • HIMSS Forum Reveals how Under-resourced Health Systems Plan to Use AI

    Jul 23 | Diagnostics World | Two of the great promises of AI is that it can help fill the gap in care in underserved communities and that it will give clinicians in high-demand specialties tools to meet that demand. One panel of experts at the HIMSS AI in Healthcare Forum in Brooklyn, NY, July 11-12, described how their organizations are implementing projects in exactly those areas. The HIMSS AI in Healthcare Forum brought together IT leaders, clinicians, and administrators to discuss how AI is being implemented in healthcare systems across the country. More

  • Biotech Launches to Find and Tackle Disease-Causing Proteins

    Jul 22 | Diagnostics World | In a proof-of-concept study, a platform integrating nanomedicine with artificial intelligence (AI) and “actual causality” analysis succeeded in pinpointing a pair of proteins thought to play key roles in the development of metastatic prostate cancer and atherosclerosis. The technology is the basis of a biotech company launching today that will use the same approach to identify potential biomarkers and drugs for treating a wide range of catastrophic diseases, including cardiovascular and neurodegenerative diseases as well as different types of cancers. More

  • Swiss Researchers Pioneer Multiomics Diagnostics for Cancer Treatment Selection

    Jul 18 | Diagnostics World | Swiss researchers have achieved a significant breakthrough in cancer diagnostics, demonstrating that advanced multiomics testing can successfully predict the most effective treatments for melanoma patients within four weeks—a timeline fast enough for real-world clinical use. More

  • Alzheimer's Biomarker Found at Surprisingly High Levels in Newborns Challenges Diagnostic Assumptions

    Jul 17 | Diagnostics World | A study has revealed that phosphorylated tau (p-tau217), a key biomarker for Alzheimer's disease diagnosis, appears at even higher levels in healthy newborns than in adults with Alzheimer's disease—a finding that could reshape how clinicians interpret this widely-used diagnostic tool. More

  • Startups Taking Multi-Cancer Early Detection Testing to the Next Level

    Jul 10 | Diagnostics World | A growing number of promising young companies are developing tests that are particularly good at picking up early cancer, initially for a single type of cancer but with the potential to eventually be extended to multiple cancer types. A handful of these startups will be spotlighted at the upcoming Next Generation Dx Summit . More

  • Fragmentation Approach to Finding Remnants of Cancer in the Blood

    Jul 09 | Diagnostics World | Molecular testing for minimal residual disease (MRD) is increasingly being used to detect cancer recurrence, and to that end many companies are actively developing assays. The tumor-informed approach based on the genetic mutations of patients has been particularly popular and often employs cell-free DNA (cfDNA) and more specifically circulating tumor DNA (ctDNA) analysis. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more